# Biotech Pipeline - Gene/Cell, Neuro & Tools - Week of June 14, 2026: In Vivo Grows Up, Lilly's $3B CAR-T Bet

> Gene, cell, neuro and tools newsletter for the week of June 14, 2026. In-vivo cell therapy got a price tag as Eli Lilly paid ~$3B upfront for an in-vivo CAR-T developer, 4DMT aimed a one-shot retinal gene therapy at the ~$20B anti-VEGF market, and RNA-editing operators leaned into reversibility.

## Biotech Pipeline: Gene/Cell, Neuro & Tools

### Week of June 14, 2026: In Vivo Grows Up, Lilly's $3B CAR-T Bet

---

For years "in vivo" was the slide everyone nodded at and nobody underwrote. This week the tape said otherwise, and not one program but the whole genre at once: a multibillion-dollar in-vivo CAR-T acquisition, a one-shot retinal gene therapy aimed at a $20 billion market, and an RNA-editing operator explaining why his modality is built to be re-dosed. Three chemistries, one message, the conversation moved from "can we" to "here's the deal, here's the clinic, here's the catalyst."

---

### TL;DR

- **Eli Lilly paid up for in-vivo CAR-T**, roughly $3 billion upfront (up to ~$7–7.5B) for a developer with early multiple-myeloma data, and Legend Biotech (LEGN) is about to drop its own in-vivo CAR-T readout at EHA. The validation is real; the durability is unproven. ([Biotech Hangout, Jun 9](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhWF1J5H67t4acQ36bUAM-2FbQx73L-2FueOJzRqmgPfZPY98dyu7D77vDqMy3018yfL4rVs5Qx-2FX7g9x8eo1W7PMqwA-2FwU7P-2FTI-2F9g2z4oE9-2BW1w-3D-3DAQlQ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUJTfP4yvTFFR0aYmMXRjb9Bj4KyMxNlabIJgN64HWw6-2FeQRQOwEitZw9pIrGrgW1X4ayXJMJ-2BvrAftVF8flGaYmSnNGkm80S46uWIFqnd9po5JNL-2BSZGAivQiG7JqFaczu-2FZb98ZVg0zznO5AAeMh27HAygIKyBj7z-2F1bzDLatWA-3D-3D))
- **4DMT (FDMT) is aiming a single-injection gene therapy at the ~$20B anti-VEGF market**, where some Phase 2 patients who needed ~10 eye injections a year are now "injection-free." The targets it's trying to displace are Regeneron's Eylea and Roche's Vabysmo. ([Pathfinders in Biopharma, Jun 13](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiC5WhQYhdTCRNQQtZS5DIHxsCVqAjEgTiYAWw5Rk0j4CUKvg3e6l6qY5fwTH2BIFcq3lnneeVXQPUWTkoSRm4-2BZdpLdfj75ylfFwZ5RaCDvg-3D-3DAcIq_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUJTfP4yvTFFR0aYmMXRjb9Bj4KyMxNlabIJgN64HWw6881op4s-2B8TFtkXiBEbvIZyixhHldO4EU-2BmGjA6LBQfUs1LwAzxtRZqemb8AHFzL-2BIlSQf1TlzHbi-2BrkopAqQTbGNl7ypzy9nedwfffR4cqEf-2F8kR0b517TpnOBBSwBGRw-3D-3D))
- **Tools is in a "healthy correction," not a collapse.** Sartorius's René Faber says 2025 was the first year biologics topped half of all pharma sales, the demand base is intact, just more volatile and more modality-diverse. ([Molecule to Market, Jun 12](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgtQKqg3Lkue6xv4BjJfyfnPZvT2BHsNxG2ut7bzPogzKPswUAf0CV2XRFgWefK-2BJXxx8H7A0BkokYhG3iWkViU4QezSi4cV1hHN6G-2BReE6xQ-3D-3D_7yO_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUJTfP4yvTFFR0aYmMXRjb9Bj4KyMxNlabIJgN64HWw68v4-2BtXvmdzUnfoW3cFfEtkZf9xRXZoJiH-2BjMggJJ4Q74sdFo1cn4fppPabIt6aN2T-2BAg3VQOxB-2Bf8ontIb71dKtVfIEWMBOYfyDvzS3P54zTfI1YNPCQAgCLEHd1HAt2w-3D-3D))

---

### What's new

**In-vivo cell therapy got a price tag, and it's a big one.** On the June 9 Biotech Hangout, the panel walked through Eli Lilly's acquisition of an in-vivo CAR-T developer for roughly $3 billion upfront (up to ~$7–7.5 billion), driven by relapsed/refractory multiple-myeloma data (BCMA). The headline is gaudy, at 18 patients, "100% ORR, 100% MRD negativity," but the hosts flagged the asterisk: by month three "one patient relapsed and another patient turned MRD positive," on median follow-up of only ~2.8 months. The same panel previewed Legend Biotech's in-vivo CAR-T at EHA, where an IV lipid-nanoparticle dose transfects T cells in the blood, no conditioning, no vein-to-vein wait, for ~100% response and 83% complete responses at the higher dose, again on ~2.2 months. ([Biotech Hangout](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhWF1J5H67t4acQ36bUAM-2FbQx73L-2FueOJzRqmgPfZPY98dyu7D77vDqMy3018yfL4rVs5Qx-2FX7g9x8eo1W7PMqwA-2FwU7P-2FTI-2F9g2z4oE9-2BW1w-3D-3Denlf_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUJTfP4yvTFFR0aYmMXRjb9Bj4KyMxNlabIJgN64HWw67GmXf1eU2zNDAJf-2Fu4DKdIzJ-2BgOXbOPqrnQ8mgr8x5afX7nS-2B9aNwT8BOVgHPQPhebjM-2BqAFzfm5WpGqzcgAUTNFU971heLGixcTA804IVJgq86vjZ-2FWahGhYT4qdOvrg-3D-3D))

**The retina is where in-vivo gene therapy meets a real, established market.** On the June 13 Pathfinders episode (recorded at RBC's healthcare conference), 4DMT's Chief Commercial & Business Officer Chris Sims made the cleanest commercial case of the week. The anti-VEGF market is "probably going to be in the range of $20 billion" globally and growing ~3%+, where incumbents win on tiny durability increments, Roche's Vabysmo is "on pace to be a $4 to $5 billion drug" this year on an extra week or two. His pitch for 4D-150: in Phase 2, "patients that were getting upwards of 10 injections on average in a year got one injection... and now, a couple years later, they are injection-free." The gate is safety, not efficacy, and he claims intraocular-inflammation rates "similar to what you would expect with Eylea." ([Pathfinders in Biopharma](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiC5WhQYhdTCRNQQtZS5DIHxsCVqAjEgTiYAWw5Rk0j4CUKvg3e6l6qY5fwTH2BIFcq3lnneeVXQPUWTkoSRm4-2BZdpLdfj75ylfFwZ5RaCDvg-3D-3DhPYe_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUJTfP4yvTFFR0aYmMXRjb9Bj4KyMxNlabIJgN64HWw652JgV05a167W5MpXJfmQyIv-2BjuI9WVPfll1qRDil66IU-2FwkzlGbTn2lVOWFyAlbKpNusIzFmFj25OqK1lDc4ZEhO5W4pYwbrUD7HHg4qorH89TfqPlr1DD1ikuV4jhA2g-3D-3D))

**And the editing operators are leaning into reversibility, not just permanence.** On the June 12 Cell & Gene podcast, Ascidian Therapeutics' Dr. Mike Ehlers laid out why RNA exon editing changes the risk calculus: "DNA editing, it's permanent, powerful, but in some ways it's kind of unforgiving... RNA exon editing can be durable, but need not necessarily be irreversible." It can also address large genes, his lead, ACDN01 in Stargardt disease, targets ABCA4, which exceeds single-vector AAV capacity. Two tells for the read-through crowd: a multi-target CNS collaboration with Roche on AAV delivery, and the line that should be tattooed on the field, "the field isn't short on innovation. It's short on repeatability." ([Cell & Gene: The Podcast](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOi3lGqEfHNn7iQnpsWosVhuS7fU0RTwTrx4Cmmo7UtNE4dfKQSjDa-2FwA86T90tR3mar2GUIGzLYUyLVTd7aknFZUs-2Fq3eXl5otBrn7Gy9BZ-2Bg-3D-3DMUqt_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUJTfP4yvTFFR0aYmMXRjb9Bj4KyMxNlabIJgN64HWw6-2BVskBqc5dbZjc0TtDzijrzilS-2F6U1T9WvoSashlURBSjM4-2FMxh5AhQxvnXc-2FqcM5Oz-2FST3o6kd-2FbCUs7KqNPStaQL4PryoW2H0YpkkJKuWWWxHNwrycZaMrdoUr9GL0pA-3D-3D))

**On tools, the operator read was reassuringly boring.** Sartorius board member René Faber told the June 12 Molecule to Market that 2025 was "the first year where the sales of biologics reached more than 50% of overall pharma drug sales," called the COVID hangover a "healthy correction and normalization," and argued the demand base is broadening across RNA, cell therapies, viral vectors, GLP-1s, ADCs and bispecifics, "the fundamental growth drivers are intact," just inside "a time of higher volatility." ([Molecule to Market](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgtQKqg3Lkue6xv4BjJfyfnPZvT2BHsNxG2ut7bzPogzKPswUAf0CV2XRFgWefK-2BJXxx8H7A0BkokYhG3iWkViU4QezSi4cV1hHN6G-2BReE6xQ-3D-3DrH4D_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUJTfP4yvTFFR0aYmMXRjb9Bj4KyMxNlabIJgN64HWw65l9UmMAVfbrxgsgkvEIQ4T3-2BhY7vtiEF8ls69Hum2U417saGHskZfafA4Tw497G-2B-2BtkDlBj9-2BahchPCCZzBM5PqFaWfY2i0fg737-2FxPdWBqM9g0aX7qTj9v7-2B1EZ8Isqw-3D-3D))

---

### The debate

**This week's real fight was about Alzheimer's biology, not launch curves, and the amyloid orthodoxy took two punches with no drugmaker on the mat to answer.** On unSILOed (Jun 8), Dr. Dale Bredesen reframed plaque as defense, not cause: amyloid as "antimicrobial" sequestration, citing Harvard's Rudy Tanzi on pathogens, herpes simplex, E. coli, candida, P. gingivalis, found "at the center of these plaques," with phospho-tau also acting as an antimicrobial. In his telling APOE4 is a pro-inflammatory "God gene," carried by ~two-thirds of Alzheimer's patients versus ~25% of the population. ([unSILOed with Greg LaBlanc](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOi1FmHSM5VHCMLKKs8tGx4U42ZUbw1h-2B5gzO7aO4MGGBzygVJCf1gLLwXfX-2B0w29HtNkuGA8atvePmgKMl0CxItiMBWoZ94EZaW4GgoOuCyDg-3D-3DaOay_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUJTfP4yvTFFR0aYmMXRjb9Bj4KyMxNlabIJgN64HWw6z4gMU5MFQdWJuahIRaShke7BVS2a8N0vv1MiHGkXgx89TfI9mhgn7J2-2BGQc3Bver1x12m0c-2BuVkoR-2BcJgI4X5tyaeU61i1zS1fmD-2BjuI5N1Hjjk8rJX-2BgRpPKhsPLaMGA-3D-3D))

Lipidologist Tom Dayspring, on The Peter Attia Drive (Jun 8), tied APOE4 to dysfunctional brain cholesterol transport that pushes amyloid-precursor cleavage toward toxic beta-amyloid 42, amyloid-consistent, but upstream of it. The fair counter-pole: Bredesen is a genuinely contrarian figure selling a lifestyle "protocol," and no operator from Biogen/Eisai or Lilly was on the tape to defend the antibody franchises. Treat the amyloid-skeptic chorus as loud but one-sided right now. One nugget for diagnostics: Dayspring flags 24S-hydroxycholesterol as a promising blood marker of brain health not yet "available outside of research studies." A gap, not a product, yet. ([The Peter Attia Drive](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgyzPBoysrQCBk-2ByM-2BfIXVukhGCOoDG1J6AYQph9HcgoWlWvYqyb7kjotF1FKpHHb8bUBXooh-2BFuADTgmIYnQummO4B0bp2rg6AZRNG7mXLRQ-3D-3DuBUV_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUJTfP4yvTFFR0aYmMXRjb9Bj4KyMxNlabIJgN64HWw69Rnm0WLMHrYfefL-2F-2FsLz0aGfjDDD2A9jTtHlozgtfJZMmPx2UqbpEzt153SyHt8685PYLsO9P9rFRtG7sPWBiMPXdLjXTtbJYjKUH4K0Oq0n6s75YFKDTXc91FV-2F3psqw-3D-3D))

---

### Read-throughs & names in play

- **Eli Lilly (LLY) / Legend (LEGN).** Lilly just set the in-vivo CAR-T price floor; Legend's EHA readout is the near-term catalyst for whether the LNP-delivered approach travels beyond one company. Bull: off-the-shelf, no conditioning, no apheresis. Bear: every dataset is under 3 months of follow-up, durability is the whole question. ([Biotech Hangout](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhWF1J5H67t4acQ36bUAM-2FbQx73L-2FueOJzRqmgPfZPY98dyu7D77vDqMy3018yfL4rVs5Qx-2FX7g9x8eo1W7PMqwA-2FwU7P-2FTI-2F9g2z4oE9-2BW1w-3D-3DkUAL_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUJTfP4yvTFFR0aYmMXRjb9Bj4KyMxNlabIJgN64HWw6ywCpPDi7jPWpE97xMD9NgM8SPE-2Bjm50-2BAyVE5iGl-2Fo-2FIl4tphHEjFH4floMJ6UBDq2RnS3gebfm97cGXSY4nevIPeFa1Mxhiqa7v-2ByrQiWD-2FdZsk5ug0FsJHrs5Bouw8A-3D-3D))
- **4DMT (FDMT), Regeneron (REGN), Roche.** If 4D-150 delivers years of anti-VEGF coverage from one shot, the Eylea/Eylea HD and Vabysmo annuity is the franchise most exposed, and the durability bar, set by Vabysmo's incremental weeks, is a low one a gene therapy is built to clear. Bear on FDMT: ocular gene therapy lives and dies on inflammation tails. ([Pathfinders in Biopharma](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiC5WhQYhdTCRNQQtZS5DIHxsCVqAjEgTiYAWw5Rk0j4CUKvg3e6l6qY5fwTH2BIFcq3lnneeVXQPUWTkoSRm4-2BZdpLdfj75ylfFwZ5RaCDvg-3D-3Dr2ht_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUJTfP4yvTFFR0aYmMXRjb9Bj4KyMxNlabIJgN64HWw6z4CG3Fhsv-2F-2Fcdmv1KXt5UlTGaWdIDuXvprDW6xwBwbeJx4IRAGGTCYixNInFkX3QMKIzawvHSA3XyCFmJ3jDQhM5TB0D0M6KGSYvKVVK4E68u02JR4rFIpUw9g-2BZbj0hQ-3D-3D))
- **In-vivo editing peers (NTLA, CRSP, BEAM, VERV, Prime, REGN collaborations).** Ascidian's "reversibility as a feature" pitch and its Roche CNS deal reinforce that delivery and re-dosing, not the editor, are where strategics are paying. The shared bottleneck remains repeatability and tissue targeting beyond liver/eye. ([Cell & Gene](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOi3lGqEfHNn7iQnpsWosVhuS7fU0RTwTrx4Cmmo7UtNE4dfKQSjDa-2FwA86T90tR3mar2GUIGzLYUyLVTd7aknFZUs-2Fq3eXl5otBrn7Gy9BZ-2Bg-3D-3DCTxV_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUJTfP4yvTFFR0aYmMXRjb9Bj4KyMxNlabIJgN64HWw65jNbxqiA-2Fnx3qX1glPaoFB11Uhwx8OvWpk-2F4ue5wDhs8vKykyoLB4-2FYeMpsUl6l-2BHttOC69gpdidw8utN4cdPa3mOSUxROHplqR2yWiUs-2B0LeK8txTplEDwPioklP6y5A-3D-3D))
- **Illumina (ILMN) and single-cell tools.** Ex-Illumina veteran Gary Schroth (18+ years, Solexa to NovaSeq), now CSO of Cellanome, argued on Mendelspod (Jun 11) that "sequencing... doesn't really explain biology" without live imaging and perturbation, a nuanced bear for sequencing-only narratives, though his platform's readout still ends in a sequencer. ([Mendelspod](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjKhDD2-2Fe-2F9Pcve-2FPwAo-2BiHelrX6NPSWUzBYH6gfr3RN7-2FcGEORvGsvZ5Y-2Fo9ZvKsKHP8OwD92MKnddgW6i5UUZxMe7iFE7lPSdOLadw893DQ-3D-3DoeVN_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUJTfP4yvTFFR0aYmMXRjb9Bj4KyMxNlabIJgN64HWw69Ht9E8Sv8gb0VuU7lmsJ-2Bo5zvlLVeJBIGRuZIpbSDLWqj6shSl6z4THVeR8Jj91g95dCNCluRr73Sjmt7EdNO8ovjjlPKcsar4SROpAh4uzoWuz2x7nVARb-2FRyKsBXCBg-3D-3D))
- **Bioprocessing (Sartorius, Repligen).** Faber's modality-diversification point is the bull case for single-use and CGT-levered consumables: more chemistries in the clinic means more distinct processes to equip. Volatility is the risk; the secular base is not. ([Molecule to Market](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgtQKqg3Lkue6xv4BjJfyfnPZvT2BHsNxG2ut7bzPogzKPswUAf0CV2XRFgWefK-2BJXxx8H7A0BkokYhG3iWkViU4QezSi4cV1hHN6G-2BReE6xQ-3D-3D7ep7_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUJTfP4yvTFFR0aYmMXRjb9Bj4KyMxNlabIJgN64HWw65OhAgdmAGRH6kwOYmsQTodkSYYdvp0DN3OoR9hdSa-2FoAUxo3z4-2BlRr5-2BnTVwS-2FJicW2MWu4n8xphxUgv6vt-2BLU-2FfTqDTUdojmxso9AaS5A-2FoS-2Fk-2BTto-2BOB-2F0tx1Wp78QA-3D-3D))

---

### What didn't show up

**No fresh anti-amyloid launch tape.** Nothing from Biogen/Eisai on Leqembi patient starts or SubQ, nothing from Lilly on Kisunla, the Alzheimer's coverage was all mechanism and prevention, not uptake. And no company-specific data from CRISPR Therapeutics, Intellia, Beam, or Verve, nor coverage of Thermo Fisher, Danaher, Agilent, Revvity, Bruker, or Waters. Where there was no tape, we left the line blank rather than fill it.